Literature DB >> 19771438

High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.

Fatma Ferda Verit1.   

Abstract

PURPOSE: The aims of the study were to investigate high sensitive serum C-reactive protein (HS-CRP) levels in normoinsulinemic polycystic ovary syndrome (PCOS) patients without metabolic syndrome and whether there was any relationship between HS-CRP and other cardiovascular risk factors such as obesity and serum lipids.
METHODS: A total of 52 normoinsulinemic PCOS women without metabolic syndrome and 48 normoandrogenic ovulatory women were enrolled in the study. Standard clinical examinations, and ultrasonographic and endocrine screening including FSH, LH, total testosterone, free testosterone, sex hormone-binding globulin, dehydroepiandrosterone sulfate, low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC) and triglyceride (TG) were measured. Normal insulin sensitivity was defined on the basis of fasting serum glucose and insulin levels, serum insulin response to an oral glucose tolerance test and homeostatic model of insulin resistance. HS-CRP was assessed spectrophotometrically.
RESULTS: PCOS patients had increased HS-CRP compared to the control group (P < 0.0001). HS-CRP was positively correlated with body mass index (BMI) (r = 0.44, P < 0.0001), waist-to-hip ratio (WHR) (r = 0.66, P < 0.0001), LDL (r = 0.62, P < 0.0001), TC (r = 0.56, P < 0.0001) and TG (r = 0.38, P < 0.0001), and negatively correlated with HDL (r = -0.45, P < 0.0001). There was also a strong association between HS-CRP and PCOS status (r = 0.69, P < 0.0001) in the study. Multivariate regression analysis demonstrated that BMI, WHR, LDL, HDL and PCOS status were also the independent variables that influenced HS-CRP in the overall group.
CONCLUSION: Elevated HS-CRP was associated with cardiovascular risk factors in normoinsulinemic PCOS without metabolic syndrome. These patients need more intensive screening or treatment for this disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19771438     DOI: 10.1007/s00404-009-1226-6

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

Review 1.  Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

Authors:  Héctor F Escobar-Morreale; Manuel Luque-Ramírez; Frank González
Journal:  Fertil Steril       Date:  2010-12-17       Impact factor: 7.329

2.  Oxidative stress markers are not valuable markers in lean and early age of polycystic ovary syndrome patients.

Authors:  E Cakir; M Ozbek; E Ozkaya; N Colak; E Cakal; M Sayki; A Gungunes; Y Aliyazicioglu; A Mentese; T Delibasi
Journal:  J Endocrinol Invest       Date:  2010-11-16       Impact factor: 4.256

3.  Clusters of anthropometric indicators of body fat associated with maximum oxygen uptake in adolescents.

Authors:  Eliane Cristina de Andrade Gonçalves; Heloyse Elaine Gimenes Nunes; Diego Augusto Santos Silva
Journal:  PLoS One       Date:  2018-03-13       Impact factor: 3.240

4.  UPLC/Q‑TOF‑MS based plasma metabolomics and clinical characteristics of polycystic ovarian syndrome.

Authors:  Xuemei Fan; Jianfa Jiang; Zhiqiang Huang; Jumei Gong; Yiming Wang; Wei Xue; Yan Deng; Yanfang Wang; Tingping Zheng; Aijun Sun; Guoan Luo
Journal:  Mol Med Rep       Date:  2018-11-12       Impact factor: 2.952

5.  Expression of microRNA in follicular fluid in women with and without PCOS.

Authors:  Alexandra E Butler; Vimal Ramachandran; Shahina Hayat; Soha R Dargham; Thomas Keith Cunningham; Manasi Benurwar; Thozhukat Sathyapalan; S Hani Najafi-Shoushtari; Stephen L Atkin
Journal:  Sci Rep       Date:  2019-11-08       Impact factor: 4.379

6.  The Role of Chronic Inflammation in Polycystic Ovarian Syndrome-A Systematic Review and Meta-Analysis.

Authors:  Shaimaa Aboeldalyl; Cathryn James; Emaduldin Seyam; Emad Moussa Ibrahim; Hossam El-Din Shawki; Saad Amer
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.